Inclusion Criteria

Inclusion

- Patients must have histologically or cytologically confirmed colorectal
adenocarcinoma that is metastatic and which has failed standard treatment or for
which no standard treatment is available

- Patients should have fluoropyrimidine-refractory disease; radiographic evidence of
progression within 4 weeks from the last dose of a fluoropyrimidine-based regimen (at
least 6 weeks of fluoropyrimidine-based treatment)

- Patients should have received and progressed on (or proved to be intolerant to)
oxaliplatin and irinotecan; progression within 6 months from oxaliplatin-based
therapy or irinotecan-based therapy is acceptable for eligibility

- Patients with KRAS wild-type or unknown KRAS status tumors should have progressed on
or within 6 months from last cetuximab or panitumumab-based therapy; no prior
cetuximab therapy is required for KRAS mutant tumors

- ECOG performance status =< 2

- Life expectancy >= 12 weeks

- Ability to understand and the willingness to sign a written informed consent document

- Ability to swallow pills

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Total bilirubin =< institutional upper limit of normal

- AST(SGOT)/ALT(SGPT) =< 3 x institutional upper limit of normal in the absence of
metastatic disease to the liver and =< 5 x institutional upper limit of normal in the
setting of metastatic disease to the liver

- Creatinine =< 1.5 x institutional upper limit of normal

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation

- Males undergoing study treatment should also agree to adequate measures of
contraception (partner contraception and use of condoms or abstinence, or vasectomy)

Exclusion

- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from significant adverse events due to agents administered more than 3
weeks earlier

- Patients may not be receiving any other investigational agents

- Patients with known brain metastases should be excluded from this clinical trial

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to vorinostat or other agents used in study

- Greater than Grade 2 neuropathy as defined by CTCAE version 3.0

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Baseline EKG with QTc prolongation that is grade 2 or higher by CTCAE version 3.0

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with vorinostat

- Patients should not have taken valproic acid or other histone deacetylase inhibitors,
for at least 4 weeks prior to enrollment

- Patients with known HIV infection or known active viral hepatitis

- Prior treatment with vorinostat

- Other non-study medications known to increase the QTc interval